JP2013545816A - インフルエンザウイルス複製阻害物質 - Google Patents

インフルエンザウイルス複製阻害物質 Download PDF

Info

Publication number
JP2013545816A
JP2013545816A JP2013544808A JP2013544808A JP2013545816A JP 2013545816 A JP2013545816 A JP 2013545816A JP 2013544808 A JP2013544808 A JP 2013544808A JP 2013544808 A JP2013544808 A JP 2013544808A JP 2013545816 A JP2013545816 A JP 2013545816A
Authority
JP
Japan
Prior art keywords
alkyl
group
independently
optionally
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013544808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545816A5 (cg-RX-API-DMAC7.html
Inventor
ポール エス． チャリフソン，
マイケル ピー． クラーク，
ユプル ケー． バンダレージ，
イオアナ デービーズ，
ジョン ピー． ダフィー，
ファイ ガオ，
ジュン フェン，
ジャンリン リャン，
ジョセフ エム． ケネディー，
マーク ダブリュー． レデボア，
ブライアン レッドフォード，
フランソワ マルタイス，
エマニュエル ペローラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2013545816A publication Critical patent/JP2013545816A/ja
Publication of JP2013545816A5 publication Critical patent/JP2013545816A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013544808A 2010-12-16 2011-12-16 インフルエンザウイルス複製阻害物質 Pending JP2013545816A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42394310P 2010-12-16 2010-12-16
US61/423,943 2010-12-16
US201161527273P 2011-08-25 2011-08-25
US61/527,273 2011-08-25
PCT/US2011/065371 WO2012083117A1 (en) 2010-12-16 2011-12-16 Inhibitors of influenza viruses replication

Publications (2)

Publication Number Publication Date
JP2013545816A true JP2013545816A (ja) 2013-12-26
JP2013545816A5 JP2013545816A5 (cg-RX-API-DMAC7.html) 2015-02-12

Family

ID=45478530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013544808A Pending JP2013545816A (ja) 2010-12-16 2011-12-16 インフルエンザウイルス複製阻害物質

Country Status (10)

Country Link
US (1) US8871774B2 (cg-RX-API-DMAC7.html)
EP (1) EP2651940A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013545816A (cg-RX-API-DMAC7.html)
KR (1) KR20140014110A (cg-RX-API-DMAC7.html)
CN (1) CN103492381A (cg-RX-API-DMAC7.html)
AU (1) AU2011343642A1 (cg-RX-API-DMAC7.html)
CA (1) CA2822057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013006836A (cg-RX-API-DMAC7.html)
RU (1) RU2013132681A (cg-RX-API-DMAC7.html)
WO (1) WO2012083117A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523225A (ja) * 2014-08-08 2017-08-17 ヤンセン・サイエンシズ・アイルランド・ユーシー インフルエンザウイルス感染に使用するためのインドール類
JP2019529386A (ja) * 2016-09-05 2019-10-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 抗インフルエンザウイルスのピリミジニル誘導体
JP2021514967A (ja) * 2018-03-05 2021-06-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
JP2021532149A (ja) * 2018-07-27 2021-11-25 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. インフルエンザウイルス複製阻害剤としてのピロロ［２，３−ｂ］ピリジン誘導体

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2442809T3 (pl) 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
DK3191489T3 (da) 2014-09-08 2021-03-29 Janssen Sciences Ireland Unlimited Co Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 十分に安定化された非対称ｓｉｒｎａ
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017089518A1 (en) 2015-11-27 2017-06-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
US10717732B2 (en) 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CA3010327A1 (en) 2016-01-20 2017-07-27 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107759571B (zh) 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2018041091A1 (en) 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
KR102554019B1 (ko) 2016-12-15 2023-07-11 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
CN108276401B (zh) * 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110799647A (zh) 2017-06-23 2020-02-14 马萨诸塞大学 双尾自递送sirna及相关的方法
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
US11820985B2 (en) 2019-03-26 2023-11-21 University Of Massachusetts Modified oligonucleotides with increased stability
JP7450017B2 (ja) 2019-07-22 2024-03-14 広東衆生睿創生物科技有限公司 ピリミジン誘導体の優位な塩形およびその結晶形
AU2020329155A1 (en) 2019-08-09 2022-03-10 University Of Massachusetts Chemically modified oligonucleotides targeting SNPs
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CN110787170B (zh) * 2019-12-19 2022-06-28 浙江立恩生物科技有限公司 一种治疗流感病毒感染的药物
CA3172168A1 (en) 2020-03-26 2021-09-30 Anastasia Khvorova Synthesis of modified oligonucleotides with increased stability
CN116323593B (zh) * 2020-10-29 2025-06-03 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531760A (ja) * 2004-03-30 2007-11-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2009525962A (ja) * 2006-01-17 2009-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なアザインドール
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829581A (en) * 1970-07-23 1974-08-13 Du Pont Aliphatic polycyclic amidoximes as influenza antiviral agents
IL83821A0 (en) 1986-09-10 1988-02-29 Sandoz Ag Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
ATE269303T1 (de) 1999-01-07 2004-07-15 Wyeth Corp Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
CA2373883A1 (en) 1999-07-02 2001-01-11 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
AU2457201A (en) 1999-12-28 2001-07-09 Bristol-Myers Squibb Company Cytokine, especially tnf-alpha, inhibitors
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
CA2421502A1 (en) 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
MXPA03001962A (es) 2000-09-06 2004-03-26 Johnson & Johnson Metodo para tratar alergias utilizando pirazoles sustituidos.
EP1322652A1 (en) 2000-09-22 2003-07-02 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
PL363241A1 (en) 2000-12-22 2004-11-15 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
DK1392697T3 (da) 2001-03-14 2005-02-14 Wyeth Corp Antidepressive azaheterocyclylmethylderivater af 2,3-dihydro-1,4-dioxino[2.3-f]quinolin
EP1381600A1 (en) 2001-04-24 2004-01-21 Wyeth, A Corporation of the State of Delaware Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
DK1401839T5 (da) 2001-04-26 2006-03-13 Wyeth Corp Antidepressive (SSSRI) azaheterocyclylmethylderivater af 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalen
US6656947B2 (en) 2001-04-26 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
US6552049B2 (en) 2001-04-26 2003-04-22 Wyeth Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans
US6617327B2 (en) 2001-04-26 2003-09-09 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
DE60201447T2 (de) 2001-04-30 2006-02-23 Wyeth Antidepressive azaheterocyclylmethylderivate von 7,8-dihydro-1,6,9-trioxa-3-azacyclopenta(a)naphthalin
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
EP1387845A2 (en) 2001-05-17 2004-02-11 Wyeth PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-(2,3-f) QUINOLINE
ATE432929T1 (de) * 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AR035083A1 (es) 2001-07-25 2004-04-14 Wyeth Corp Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003237121A1 (en) 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
KR20050032105A (ko) 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 피라졸 조성물
AU2002368154A1 (en) 2002-08-08 2004-02-25 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
RS52386B (sr) 2003-02-26 2013-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Dihidropteridinoni, postupak za njihovo pripremanje i njihova primena kao leka
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
RU2006138621A (ru) 2004-04-02 2008-05-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101068815B (zh) 2004-10-04 2012-09-05 千禧药品公司 有效作为蛋白激酶抑制剂的内酰胺化合物
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2005304784B2 (en) * 2004-11-04 2011-03-24 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
CA2587926A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
KR20070095952A (ko) 2004-12-16 2007-10-01 버텍스 파마슈티칼스 인코포레이티드 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2596830A1 (en) 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
CN101218241B (zh) 2005-05-16 2011-02-16 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
KR20080063809A (ko) 2005-09-30 2008-07-07 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 데아자퓨린
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
WO2007095223A2 (en) 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CA2648250A1 (en) 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20090017444A1 (en) 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
US8129387B2 (en) 2006-12-14 2012-03-06 Vertex Pharmaceuticals Incorporated Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors
WO2008079346A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
NZ579446A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
WO2008112646A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
AU2008226466B2 (en) 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
JP5087640B2 (ja) 2007-03-22 2012-12-05 武田薬品工業株式会社 Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
WO2009023269A2 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
CA2700979C (en) 2007-09-28 2017-06-20 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
EP2197901B1 (en) 2007-10-09 2013-12-11 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
WO2009073300A1 (en) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
KR20110033239A (ko) 2008-06-23 2011-03-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
CN102076690A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
WO2010011762A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2011000843A (es) 2008-07-23 2011-04-11 Vertex Pharma Inhibidores de pirazolopiridin cinasa triciclicos.
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011011653A (es) 2009-05-06 2012-01-20 Vertex Pharma Pirazolopiridinas.
PL2442809T3 (pl) * 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
CN102985424B (zh) 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
US20130040933A1 (en) 2010-04-27 2013-02-14 Brandon Cash Azaindoles as janus kinase inhibitors
KR20130128435A (ko) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
WO2012083121A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531760A (ja) * 2004-03-30 2007-11-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2009525962A (ja) * 2006-01-17 2009-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なアザインドール
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523225A (ja) * 2014-08-08 2017-08-17 ヤンセン・サイエンシズ・アイルランド・ユーシー インフルエンザウイルス感染に使用するためのインドール類
JP2019529386A (ja) * 2016-09-05 2019-10-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 抗インフルエンザウイルスのピリミジニル誘導体
JP2021514967A (ja) * 2018-03-05 2021-06-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
JP7031002B2 (ja) 2018-03-05 2022-03-07 広東衆生睿創生物科技有限公司 ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
JP2021532149A (ja) * 2018-07-27 2021-11-25 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. インフルエンザウイルス複製阻害剤としてのピロロ［２，３−ｂ］ピリジン誘導体
JP7522722B2 (ja) 2018-07-27 2024-07-25 コクリスタル ファーマ，インコーポレイテッド インフルエンザウイルス複製阻害剤としてのピロロ［２，３－ｂ］ピリジン誘導体
US12357631B2 (en) 2018-07-27 2025-07-15 Cocrystal Pharma, Inc. Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication

Also Published As

Publication number Publication date
RU2013132681A (ru) 2015-01-27
KR20140014110A (ko) 2014-02-05
AU2011343642A1 (en) 2013-05-02
EP2651940A1 (en) 2013-10-23
US20140005192A1 (en) 2014-01-02
MX2013006836A (es) 2013-09-26
CA2822057A1 (en) 2012-06-21
CN103492381A (zh) 2014-01-01
WO2012083117A1 (en) 2012-06-21
US8871774B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
JP2013545816A (ja) インフルエンザウイルス複製阻害物質
US10875855B2 (en) Inhibitors of influenza viruses replication
DK3141252T3 (en) INHIBITORS OF INFLUENZA VIRUS REPLICATION
JP2013545818A (ja) インフルエンザウイルス複製阻害物質
JP2013545817A (ja) インフルエンザウイルス複製阻害物質
WO2013184985A1 (en) Inhibitors of influenza viruses replication
HK1190699A (en) Inhibitors of influenza viruses replication
HK1193810A (en) Inhibitors of influenza viruses replication
HK1190700A (en) Inhibitors of influenza viruses replication
OA17028A (en) Inhibitors of influenza viruses replication.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160510